Table 3.
Characteristics of Patients With and Without LVEF Improvement
| LVEF Improvement | Present (n = 23) | Absent (n = 18) | p Value |
|---|---|---|---|
| Clinical variables | |||
| Age, yrs | 51 ± 7.5 | 57 ± 11 | 0.06 |
| Men | 18 (78) | 11 (61) | 0.31 |
| Hypertension | 14 (60) | 12 (66) | 0.99 |
| Diabetes mellitus | 4 (17) | 5 (27) | 0.70 |
| Dyslipidemia | 5 (21) | 8 (44) | 0.18 |
| NYHA functional class | |||
| I | 4 (17) | 0 | 0.11 |
| II | 7 (30) | 7 (39) | 0.57 |
| III | 10 (43) | 8 (44) | 0.95 |
| IV | 2 (9) | 3 (17) | 0.64 |
| Hemodynamic variables | |||
| Resting SBP, mm Hg | 125 ± 14 | 128 ± 18 | 0.61 |
| Resting DBP, mm Hg | 83 ± 9 | 77 ± 11 | 0.09 |
| Resting heart rate, beats/min | 78 ± 12 | 86 ± 11 | 0.04 |
| Echocardiographic variables | |||
| Left atrial dimension index, cm/m2 | 2.34 ± 0.45 | 2.46 ± 0.44 | 0.41 |
| LVEDVI, ml/m2 | 81 ± 18 | 88 ± 18 | 0.23 |
| LVESVI, ml/m2 | 59.6 ± 21 | 66 ± 20 | 0.33 |
| LVEF, % | 29 ± 12 | 26 ± 12 | 0.45 |
| Resting LV WMSI | 2.63 ± 0.54 | 2.77 ± 0.60 | 0.44 |
| Resting RV WMSI | 1.51 ± 0.77 | 1.70 ± 0.86 | 0.45 |
| ICR present | 16 (70) | 4 (22) | 0.003 |
| Medications | |||
| Beta-blocker | 15 (65) | 16 (89) | 0.14 |
| ACE-I or ARB | 14 (60) | 11 (61) | 1.00 |
| Diuretics | 10 (43) | 10 (55) | 0.54 |
| HIV-associated factors | |||
| CD4 count, cell/mm3 | 257 (116/394) | 211 (62/329) | 0.50 |
| Viral load copies/ml | 159 (<50/6,365) | 1874 (<50/36,100) | 0.52 |
| Duration of HIV infection, yrs | 9 ± 5.9 | 11 ± 7.2 | 0.29 |
| Antiretroviral therapy | 18 (78) | 13 (72) | 0.72 |